<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570778</url>
  </required_header>
  <id_info>
    <org_study_id>CQVA149A2204</org_study_id>
    <nct_id>NCT00570778</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Multicentre Study to Determine the Effect of QVA149 on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of QVA149 in patients with moderate to
      severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute measurements post dosing. Baseline FEV1 is the mean of the 45 minute and 15 minute pre-dose FEV1 values at day 1 of each period. Least square means are based on the Analysis of Covariance Trough FEV1 at day 7 = sequence effect + patient(sequence) + period effect + treatment effect + (period) baseline FEV1 + error.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve (AUC) 5 Minutes-12 Hours at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Spirometry testing was performed in accordance with American Thoracic Society standards. FEV1 was assessed at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on Day 7. Standardized (with respect to time) AUC (5 minutes-12 hours) for FEV1 on day 7 was calculated using the trapezoidal rule. Least square means are based on the Analysis of Covariance: FEV1 AUC = sequence effect + patient (sequence) + period + treatment + baseline FEV1 (period) + error.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events</measure>
    <time_frame>47 days</time_frame>
    <description>Additional information about adverse events can be found in the Adverse Event Section.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>indacaterol/glycopyrrolate 300/50 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indacaterol 600 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indacaterol 300 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indacaterol/glycopyrrolate</intervention_name>
    <description>Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
    <arm_group_label>indacaterol/glycopyrrolate 300/50 μg</arm_group_label>
    <other_name>QVA149</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indacaterol</intervention_name>
    <description>Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
    <arm_group_label>indacaterol 600 μg</arm_group_label>
    <arm_group_label>indacaterol 300 μg</arm_group_label>
    <other_name>QAB149</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure.

          2. Patients with moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD)
             according to the Global Initiative for Obstructive Lung Disease (GOLD) Guidelines
             2006.

          3. Patients who have smoking history of at least 10 pack years.

          4. Patients with a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) ≥30%
             and &lt; 80% of the predicted normal and post-bronchodilator FEV1/Forced Vital Capacity
             (FVC) &lt;0.70.

        Exclusion Criteria:

          1. Pregnant or nursing women, or women of child-bearing potential, regardless of whether
             or not sexually active if they are not using acceptable methods of contraception.

          2. Patients requiring long term oxygen therapy (&gt; 15 hours a day) on a daily basis for
             chronic hypoxemia, or who have been hospitalized or visited an emergency department
             for a COPD exacerbation or as result of their airways disease in the 6 weeks prior to
             screening.

          3. Patients who have had a respiratory tract infection within 6 weeks prior to screening.

          4. Patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed
             by chest x-ray to be no longer active) or clinically significant bronchiectasis.

          5. Patients with any history of asthma indicated by (but not limited to) a blood
             eosinophil count &gt; 400/mm3.

          6. Patients who, in the judgment of the investigator or the responsible Novartis
             personnel, have a clinically relevant laboratory abnormality or a clinically
             significant condition.

          7. Patients with uncontrolled Type I and Type II diabetes.

          8. History of malignancy of any organ system (including lung cancer), treated or
             untreated, within the past 5 years.

          9. Patients who are contraindicated for or who have shown an untoward reaction to inhaled
             anticholinergic agents.

         10. Patients with a history of long QT syndrome or whose QTc interval (Fridericia method)
             measured at screening is prolonged (&gt;450 ms for males or &gt;470 ms for females).

         11. Patients with a history of untoward reactions to sympathomimetic amines, inhaled
             medication or any component thereof, or any of the study drugs or drugs with similar
             chemical structures.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Jambes</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Saint Vith</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Moncton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bad Worishofen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Rudersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigator site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>January 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2013</results_first_posted>
  <disposition_first_submitted>May 8, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 8, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 10, 2012</disposition_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QVA, Indacaterol, Glycopyrrolate, Concept1, COPD, cross over study, safety and efficacy, trough FEV1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was 4 arm crossover study. There was a 7 day washout period between each treatment period. 154 patients were randomized, 153 participants received study drug. 5 patients were excluded from the Modified Intent-to-treat population (MITT). 4 patients for protocol violations and 1 patient was randomized but did not receive study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A: Ind 300 μg- Ind 600 μg- Placebo- Ind/Glyc 300/50 μg</title>
          <description>Treatment Period 1: One indacaterol (Ind) 300 μg capsule and one placebo capsule inhaled once daily via a single dose dry powder inhaler (SDDPI) for 7 days.
Treatment Period 2: Two indacaterol 300 μg capsules inhaled once daily via a SDDPI for 7 days.
Treatment Period 3: Two placebo capsules inhaled once daily via a SDDPI for 7 days.
Treatment Period 4: One indacaterol/glycopyrrolate (Ind/Glyc) 300/50 μg and one placebo capsule inhaled once daily via a SDDPI for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>B: Ind 600 μg- Placebo- Ind/Glyc 300/50 μg- Ind 300 μg</title>
          <description>Treatment Period 1: Two indacaterol 300 μg capsules inhaled once daily via a SDDPI for 7 days.
Treatment Period 2: Two placebo capsules inhaled once daily via a SDDPI for 7 days.
Treatment Period 3: One indacaterol/glycopyrrolate (Ind/Glyc) 300/50 μg and one placebo capsule inhaled once daily via a SDDPI for 7 days.
Treatment Period 4: One indacaterol (Ind) 300 μg capsule and one placebo capsule inhaled once daily via a SDDPI for 7 days.</description>
        </group>
        <group group_id="P3">
          <title>C: Ind/Glyc 300/50 μg- Ind 300 μg- Ind 600 μg- Placebo</title>
          <description>Treatment Period 1: One indacaterol/glycopyrrolate (Ind/Glyc) 300/50 μg and one placebo capsule inhaled once daily via a SDDPI for 7 days.
Treatment Period 2: One indacaterol (Ind) 300 μg capsule and one placebo capsule inhaled once daily via a SDDPI for 7 days.
Treatment Period 3: Two indacaterol 300 μg capsules inhaled once daily via a SDDPI for 7 days.
Treatment Period 4: Two placebo capsules inhaled once daily via a SDDPI for 7 days.</description>
        </group>
        <group group_id="P4">
          <title>D: Placebo- Ind/Glyc 300/50 μg- Ind 300 μg- Ind 600 μg</title>
          <description>Treatment Period 1: Two placebo capsules inhaled once daily via a SDDPI for 7 days.
Treatment Period 2: One indacaterol/glycopyrrolate (Ind/Glyc) 300/50 μg and one placebo capsule inhaled once daily via a SDDPI for 7 days.
Treatment Period 3: One indacaterol (Ind) 300 μg capsule and one placebo capsule inhaled once daily via a SDDPI for 7 days.
Treatment Period 4: Two indacaterol 300 μg capsules inhaled once daily via a SDDPI for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population: Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="41">Safety Population included all participants who received at least 1 dose of any study drug.</participants>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-treat Population</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Population</title>
          <description>Participants were randomized and received the following 4 treatments: 1-Two placebo capsules inhaled once daily via a SDDPI for 7 days, 2-One indacaterol/glycopyrrolate (Ind/Glyc) 300/50 μg and one placebo capsule inhaled once daily via a SDDPI for 7 days, 3-One Indacaterol (Ind) 300 μg capsule and one placebo capsule inhaled once daily via a SDDPI for 7 days and 4-Two Indacaterol 300 μg capsules inhaled once daily via a SDDPI for 7 days. There was a 7 day washout period between the four treatment periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline characteristics are based on the Safety Population that consists of all participants who received study drug.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7</title>
        <description>Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute measurements post dosing. Baseline FEV1 is the mean of the 45 minute and 15 minute pre-dose FEV1 values at day 1 of each period. Least square means are based on the Analysis of Covariance Trough FEV1 at day 7 = sequence effect + patient(sequence) + period effect + treatment effect + (period) baseline FEV1 + error.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Participants from the Modified Intent-to-treat population (includes all participants who received study drug) with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol/Glycopyrrolate 300/50 μg</title>
            <description>One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 300 μg</title>
            <description>One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 600 μg</title>
            <description>Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7</title>
          <description>Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute measurements post dosing. Baseline FEV1 is the mean of the 45 minute and 15 minute pre-dose FEV1 values at day 1 of each period. Least square means are based on the Analysis of Covariance Trough FEV1 at day 7 = sequence effect + patient(sequence) + period effect + treatment effect + (period) baseline FEV1 + error.</description>
          <population>Participants from the Modified Intent-to-treat population (includes all participants who received study drug) with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.512" spread="0.0143"/>
                    <measurement group_id="O2" value="1.389" spread="0.0144"/>
                    <measurement group_id="O3" value="1.395" spread="0.0143"/>
                    <measurement group_id="O4" value="1.286" spread="0.0145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve (AUC) 5 Minutes-12 Hours at Day 7</title>
        <description>Spirometry testing was performed in accordance with American Thoracic Society standards. FEV1 was assessed at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on Day 7. Standardized (with respect to time) AUC (5 minutes-12 hours) for FEV1 on day 7 was calculated using the trapezoidal rule. Least square means are based on the Analysis of Covariance: FEV1 AUC = sequence effect + patient (sequence) + period + treatment + baseline FEV1 (period) + error.</description>
        <time_frame>Day 7</time_frame>
        <population>Participants from the Modified Intent-to-treat population (includes all participants who received study drug) with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol/Glycopyrrolate 300/50 μg</title>
            <description>One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 300 μg</title>
            <description>One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 600 μg</title>
            <description>Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve (AUC) 5 Minutes-12 Hours at Day 7</title>
          <description>Spirometry testing was performed in accordance with American Thoracic Society standards. FEV1 was assessed at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on Day 7. Standardized (with respect to time) AUC (5 minutes-12 hours) for FEV1 on day 7 was calculated using the trapezoidal rule. Least square means are based on the Analysis of Covariance: FEV1 AUC = sequence effect + patient (sequence) + period + treatment + baseline FEV1 (period) + error.</description>
          <population>Participants from the Modified Intent-to-treat population (includes all participants who received study drug) with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.610" spread="0.0180"/>
                    <measurement group_id="O2" value="1.473" spread="0.0181"/>
                    <measurement group_id="O3" value="1.457" spread="0.0180"/>
                    <measurement group_id="O4" value="1.317" spread="0.0185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events</title>
        <description>Additional information about adverse events can be found in the Adverse Event Section.</description>
        <time_frame>47 days</time_frame>
        <population>Safety population includes all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol/Glycopyrrolate 300/50 μg</title>
            <description>One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 300 μg</title>
            <description>One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Indacaterol 600 μg</title>
            <description>Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events</title>
          <description>Additional information about adverse events can be found in the Adverse Event Section.</description>
          <population>Safety population includes all participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations Due to Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Indacaterol/Glycopyrrolate 300/50 μg</title>
          <description>One indacaterol/glycopyrrolate 300 μg /50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Indacaterol 300 μg</title>
          <description>One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Indacaterol 600 μg</title>
          <description>Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

